Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; povidone; magnesium stearate - inoperable prostatic carcinoma. to suppress flare with initial luteinising hormone releasing hormone (lhrh) analogue therapy; in long-term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; maize starch - inoperable prostatic carcinoma. because of its anti-androgenic effect cyprostat is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or intolerant of oestrogen therapy. indications as at 18 may 2005 : inoperable prostatic carcinoma. * to suppress flare with initial lhrh analogues therapy. * in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. * in the treatment of hot flushes in pateinets treated with lhrh analogues or who have had orchiectomy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; povidone - inoperable prostatic carcinoma. because of its anti-androgenic effect androcur is indicated for the treatment of inoperable prostatic carcinoma in patients who have failed primary hormonal manipulation or who are at risk from cardiovascular disease and/or who are intolerant of oestrogen therapy. indications as at 1 june 1995: inoperable prostatic carcinoma to suppress 'flare' with initial lhrh analogue therapy; in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred; in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate -

Australia - inglés - Department of Health (Therapeutic Goods Administration)

eris pharmaceuticals (australia) pty ltd - cyproterone acetate -

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

bayer new zealand limited - cyproterone acetate 50mg;   - tablet - 50 mg - active: cyproterone acetate 50mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone

Canadá - inglés - Health Canada

bayer inc - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents

Canadá - inglés - Health Canada

laboratoire riva inc. - cyproterone acetate - tablet - 50mg - cyproterone acetate 50mg - other miscellaneous therapeutic agents